Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib plus paclitaxel/carboplatin for advanced or metastatic non-small cell lung cancer
ACTRN12609000247279Phase 3Terminated
- Sponsor
- National Health and Medical Research Council
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Cediranib + paclitaxel/carboplatin with Placebo + paclitaxel/carboplatin (2 arms). Primary endpoint: Overall survival. Started Jun 2009; status: terminated.
02
Drugs
cediranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12609000247279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000247279.